omniture
ASIERIS江苏亚虹医药科技有限公司

Latest News

Asieris Announces First Patient Administration in the Global Phase III Clinical Trial for APL-1702

SHANGHAI, Nov. 11, 2020 /PRNewswire/ -- Asieris Pharmaceuticals, a China-based biotech company with...

2020-11-11 17:08 585

Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC)

SHANGHAI, Nov. 5, 2020 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a China-based biotech com...

2020-11-05 13:59 602

Asieris' APL-1501 Approved for Phase I Clinical Trial in Australia

SHANGHAI, Oct. 29, 2020 /PRNewswire/ -- Asieris Pharmaceuticals, a China-based biotech company spec...

2020-10-29 09:35 654

Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL)

SHANGHAI, July 8, 2020 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a China-based biotech com...

2020-07-08 22:00 705

Asieris Wins Questex's Fierce Innovation Awards - Life Sciences Edition 2019

SHANGHAI, Dec. 19, 2019 /PRNewswire/ -- Asieris, a China-based biotech company specializing in the ...

2019-12-19 13:51 824

Asieris and Photocure Enter into a License Agreement for World-Wide Development and Commercialization of Cevira®

SHANGHAI and OSLO, Norway, July 2, 2019 /PRNewswire/ -- Asieris MediTech Co, Ltd (Asieris), aChina-...

2019-07-02 21:40 1896

Asieris Announces Completion of Enrollment for its US APL-1202 Phase Ib Clinical Trial

SHANGHAI, June 24, 2019 /PRNewswire/ -- Asieris, a China-based biotech company specializing in the ...

2019-06-24 09:00 1187